Home / Resources / Early Clinical resources

早期临床

精选资源

Certara Appoints Dr. Britta Wagenhuber as Head of Quantitative Systems Pharmacology (QSP) Consultancy

公告

Upcoming early clinical webinars

网络研讨会

Optimal Dosing, Optimal Outcomes: Model-Based Approaches for Antibody–Drug Conjugates (ADCs)

2026 年 4 月 23 日 – 3-4pm (JST) and 10-11am (CET)

网络研讨会

Accelerate Decisions with Certara IQ™: Scalable, AI-Driven QSP for Drug Development

2026 年 4 月 28 日 – 10:00-11:00am

网络研讨会

Pinnacle 21 Community or Enterprise: How to decide which is right for your study

Apr 29, May 1

Latest early clinical blogs

All Early clinical - Blog

Blog

降低药物开发风险：早期开发中的关键化学、制造和控制（CMC）及基于生理的药代动力学（PBPK）方法

在以下活动中与我们的专家会面

现场活动

Certara Biotech Forum: Workshop on Developing Investor-Ready Strategies

2026 年 5 月 7 日 – San Diego, CA

现场活动

Phoenix Roadshow 2026 – 英国剑桥

2026 年 5 月 15 日

会议

CDISC EU 2026

May 18 - 22, 2026 – Milan, Italy

All early clinical resources

Mean Residence Time (MRT): Understanding How Long Drug Molecules Stay in the Body

Modeling and Simulation - PK/PD, Blog, Knowledge Base

When pharmacokinetics meets pharmacogenomics: Genetic Insights into Fluoxetine PK for Personalized Antidepressant Therapy

Certara Products - Phoenix, Certara University, Clinical Pharmacology, Modeling and Simulation - PK/PD, Webinar

PK Parameters Explained: From Cmax to Clearance (and Why It Matters for Development Decisions)

Certara Products - Phoenix, Clinical Pharmacology, Modeling and Simulation - PK/PD, Blog

Final ICH M15 Guidance: Aligning MIDD with Global Regulatory Expectations

Certara Products, Certara Products - Phoenix, Certara Products - Simcyp, Certara Services, Clinical Pharmacology, Drug Development, Model Informed Drug Development, Modeling and Simulation, Modeling and Simulation - PBPK, Modeling and Simulation - PK/PD, Modeling and Simulation - QSP, Webinar

Integrated Population Pharmacokinetic, Pharmacodynamic, and Safety Analyses to Inform Dosage Selection in the Clinical Development of the ATR Inhibitor Tuvusertib

Certara Services, Clinical Pharmacology, Clinical Trials, Drug Development, Drug Safety, Model Informed Drug Development, Modeling and Simulation - PK/PD, Therapeutic Specialties, Publication

Platforms for collaboration between sponsors and CROs: 5 ways CROs can scale efficiently while maximizing validation assurance

Certara Products - Pinnacle 21, Blog

Data Fabrics in Pharma: Connecting Data for Better Decisions

Certara Products, Certara.AI, Drug Development, Blog

Pinnacle 21 Community or Enterprise: How to decide which is right for your study

Certara Products - Pinnacle 21, Clinical Trials, Data Standards, Webinar

How Bayesian Design Is Reshaping Clinical Development

Certara Services, Press Coverage, Video

Where Did the 80-125% Bioequivalence Criteria Come From?

Modeling and Simulation - PK/PD, Blog, Knowledge Base

Integrated PK/PD Modeling and Machine Learning to Support CNS Compound Selection

Certara Products - Phoenix, Clinical Pharmacology, Modeling and Simulation - PK/PD, Case Study

Paediatric development of radiopharmaceutical imaging agents and radioligand therapeutics

Clinical Pharmacology, Drug Development, Drug Safety, Model Informed Drug Development, Modeling and Simulation, Modeling and Simulation - PK/PD, Therapeutic Specialties, Publication

1
2
3
……
66
›

订阅时事通讯

为什么订阅？因为改变药物开发不仅是我们的目标，更是我们的执着追求。如果这也是您的想法，那么请第一时间了解新见解，与我们一起推动科学发展。

早期临床

最新资源

Modeling Hope: From Patient to Scientist Ellen Swanson on QSP, Breast Cancer, and Hope Through Science

Mean Residence Time (MRT): Understanding How Long Drug Molecules Stay in the Body

PK Parameters Explained: From Cmax to Clearance (and Why It Matters for Development Decisions)

Certara Appoints Dr. Britta Wagenhuber as Head of Quantitative Systems Pharmacology (QSP) Consultancy

精选资源

Certara Appoints Dr. Britta Wagenhuber as Head of Quantitative Systems Pharmacology (QSP) Consultancy

Upcoming early clinical webinars

Optimal Dosing, Optimal Outcomes: Model-Based Approaches for Antibody–Drug Conjugates (ADCs)

Accelerate Decisions with Certara IQ™: Scalable, AI-Driven QSP for Drug Development

Pinnacle 21 Community or Enterprise: How to decide which is right for your study

Latest early clinical blogs

药物开发中 PK/PD 建模的机器学习

美国 FDA MIDD 配对试点计划如何帮助赞助商

揭秘临床 DDI 研究：精准测量代谢产物

为何 FDA 批准 omaveloxolone 用于治疗弗里德赖希共济失调症意义重大

细胞疗法开发的主要考虑因素

降低药物开发风险：早期开发中的关键化学、制造和控制（CMC）及基于生理的药代动力学（PBPK）方法

在以下活动中与我们的专家会面

Certara Biotech Forum: Workshop on Developing Investor-Ready Strategies

Phoenix Roadshow 2026 – 英国剑桥

CDISC EU 2026

All early clinical resources

Mean Residence Time (MRT): Understanding How Long Drug Molecules Stay in the Body

When pharmacokinetics meets pharmacogenomics: Genetic Insights into Fluoxetine PK for Personalized Antidepressant Therapy

PK Parameters Explained: From Cmax to Clearance (and Why It Matters for Development Decisions)

Final ICH M15 Guidance: Aligning MIDD with Global Regulatory Expectations

Integrated Population Pharmacokinetic, Pharmacodynamic, and Safety Analyses to Inform Dosage Selection in the Clinical Development of the ATR Inhibitor Tuvusertib

Platforms for collaboration between sponsors and CROs: 5 ways CROs can scale efficiently while maximizing validation assurance

Data Fabrics in Pharma: Connecting Data for Better Decisions

Pinnacle 21 Community or Enterprise: How to decide which is right for your study

How Bayesian Design Is Reshaping Clinical Development

Where Did the 80-125% Bioequivalence Criteria Come From?

Integrated PK/PD Modeling and Machine Learning to Support CNS Compound Selection

Paediatric development of radiopharmaceutical imaging agents and radioligand therapeutics

订阅时事通讯

快捷链接

解决方案

联系我们